04:33 PM EDT, 10/30/2025 (MT Newswires) -- Edwards Lifesciences ( EW ) reported Q3 adjusted earnings late Thursday of $0.67 per diluted share, flat from a year earlier.

Analysts polled by FactSet expected $0.60.

Revenue for the three months ended Sept. 30 was $1.55 billion, up from $1.35 billion a year earlier.

Analysts surveyed by FactSet expected $1.50 billion.

The company expects Q4 adjusted EPS of $0.58 to $0.64 on revenue of $1.51 billion to $1.59 billion. Analysts expect EPS of $0.62 on revenue of $1.54 billion.

The company also raised its full-year 2025 adjusted EPS guidance to $2.56 to $2.62 from $2.45 to $2.55 earlier. Analysts expect $2.51.